<DOC>
	<DOCNO>NCT00005638</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell . PURPOSE : Phase I trial study effectiveness chemotherapy plus radiation therapy treat patient advanced cancer esophagus .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Radiation Therapy Treating Patients With Esophageal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine dose limit toxicity irinotecan give weekly cisplatin concurrent external beam multifield radiotherapy patient locally advance carcinoma esophagus gastroesophageal junction . - Determine maximum tolerate dose recommended phase II dose irinotecan regimen patient population . - Evaluate complete response rate patient one course induction chemotherapy follow concurrent chemotherapy radiotherapy . OUTLINE : This dose escalation study irinotecan . Patients receive induction chemotherapy cisplatin IV 30 minute follow irinotecan IV 30 minute day 1 , 8 , 15 , 22 . Following 2 week rest , patient begin chemoradiation . Patients receive cisplatin irinotecan day 1 , 8 , 22 , 29 radiotherapy daily 5 day week 5-6 week . Cohorts 3-6 patient receive escalate dos irinotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Patients follow every 3 month 2 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 3-24 patient accrue study .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma adenocarcinoma esophagus gastroesophageal junction T1 , N1 , M0 T24 , Nx , M0 No supraclavicular celiac lymph nod Previously untreated , newly diagnose tumor OR Prior resection without adjuvant therapy local regional failure Positive microscopic margin resection gross disease allow provide metastatic disease No positive malignant cytology pleura , pericardium , peritoneum No biopsy proven tumor invasion tracheobronchial tree tracheoesophageal fistula PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % OR ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9.0 g/dL Hepatic : Bilirubin great 1.5 mg/dL No known Gilbert 's disease Renal : Creatinine great 1.5 mg/dL No hypercalcemia Cardiovascular : No New York Heart Association class III IV heart disease No myocardial infarction within past 6 month No uncontrolled hypertension Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No severe concurrent condition ( e.g. , severe uncontrolled diabetes , uncontrolled infection , cerebral vascular disease ) No malignancy within past 5 year except basal cell carcinoma skin carcinoma situ cervix No history seizure disorder currently receive phenytoin , phenobarbital , antiepileptic medication No concurrent medical psychiatric condition disease would preclude study entry PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy esophageal cancer include adjuvant chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy esophageal cancer include adjuvant radiotherapy No prior mantle , chest , pelvic , hemibody radiotherapy Surgery : See Disease Characteristics Other : No concurrent prochlorperazine day irinotecan administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage II gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>